FDA Clearance Tracker · P020004
EXCLUDER BIFURCATED ENDOPROSTHESIS
Last checked: Nov 20, 2026Latest source record: Nov 6, 2002 (this decision)Source: openFDAMethods & limitations
Decided
Nov 6, 2002
Approved
Time to decision
287 days
Received Jan 23, 2002. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P020004
- Device name
- EXCLUDER BIFURCATED ENDOPROSTHESIS
- Applicant
- W. L. Gore & Associates, Inc.
- Applicant location
- Phonix, AZ
- Received
- Jan 23, 2002
- Decided
- Nov 6, 2002
- Decision
- Approved
- Supplements
- 199 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE EXCLUDER BIFURCATED ENDOPROSTHESIS. THE EXCLUDER BIFURCATED ENDOPROSTHESIS IS INTENDED TO EXCLUDE THE ANEURYSM FROM THE BLOOD CIRCULATION IN PATIENTS DIAGNOSED WITH INFRARENAL ABDOMINAL AORTIC ANEURYSMS (AAA) DISEASE AND WHO HAVE APPROPRIATE ANATOMY AS DESCRIBED: 1) ADEQUATE ILIAC/FEMORAL ACCESS 2) INFRARENAL AORTIC NECK TREATMENT DIAMETER RANGE OF 19-26 MM AND A MINIMUM AORTIC NECK LENGTH OF 15 MM 3) PROXIMAL AORTIC NECK ANGULATION <= 60 DEGREES 4) ILIAC ARTERY TREATMENT DIAMETER RANGE OF 8-13.5 MM AND ILIAC DISTAL VESSEL SEAL ZONE LENGTH OF AT LEAST 10 MM. THE AORTIC AND ILIAC EXTENDER ENDOPROSTHESES ARE INTENDED TO BE USED AFTER DEPLOYMENT OF THE EXCLUDER BIFURCATED ENDOPROSTHESIS. THESE EXTENSIONS ARE INTENDED TO BE USED WHEN ADDITIONAL LENGTH AND/OR SEALING FOR ANEURISMAL EXCLUSION IS DESIRED.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MIH. The earliest in FDA's data is P990017, decided Sep 28, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for W. L. Gore & Associates, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- GORE® VIABAHN® VBX Balloon Expandable EndoprosthesisPMA supplement
P160021-S051 · Decided Oct 8, 2026 · 244 days after receipt · Panel Track
Device type: Iliac covered stent, arterial (PRL) · Cardiology
- GORE® VIABAHN® FORTEGRA Venous StentBreakthroughPMA
P250017 · Decided Dec 19, 2025 · 182 days after receipt
Device type: Stent, vena cava (QTL) · Cardiology
K250410 · Decided Jun 2, 2025 · 109 days after receipt
Device type: Catheter, Percutaneous (DQY) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.